Login to Your Account



Separate Crohn's Outcomes Positive

Trials With ABT-199 Held Up; Patient Death on AbbVie Drug?

By Randy Osborne
Staff Writer

Friday, February 15, 2013
science.jpg

Backing up the European approval of Humira (adalimumab) with more data, Abbott spinout AbbVie for the first time offered long-term, patient-reported health outcomes data from the Phase III IMAgINE-1 trial in young people with Crohn's disease, along with favorable results of a caregiver survey.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription